Biomeme is a consumer medical technology company that turns your smartphone into a mobile DNA diagnostics lab that delivers test results to the palm of your hand in about 30 minutes.
Here’s how to understand why this concept is so revolutionary: Imagine a person has an issue that requires an STD test. The thought of it is certainly unpleasant, but for the individual requiring the test, it becomes even worse due to the stress of waiting days and even weeks to receive the results from their test. Biomeme eliminates this dilemma, and delivers the diagnosis before the individual leaves the doctor’s office. This allows the doctor to initiate treatment immediately. This is the tip of the iceberg for Biomeme.
Biomeme’s first test is for the 2nd most reported infectious disease in the United States: Gonorrhea. The market size for this test alone is over $2 billion. Biomeme plans to expand its test offerings into other critical STDs (at least a $71B market), as well as other infectious diseases including flu, strep throat, Dengue fever, Lyme disease, and West Nile virus. Imagine all of this being disintermediated and powered by your smartphone.
What makes Biomeme even more intriguing is the company’s long-term strategy to pursue potential applications of its technology beyond infectious disease. Agriculture, anti-counterfeiting, bio-terror threat detection, veterinary pet care, and environmental monitoring are just a handful of the areas the Biomeme team is exploring. They have already lined up paying customers in several of these long-term markets, including agencies within the US Department of Defense.